Ardelyx
ARDX • NASDAQ
Ardelyx is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Michael G. Raab, with a market cap of $1.3B.
CEOMichael G. Raab
Next Earnings
Upcoming earnings announcement for Ardelyx
Date
Thursday, April 30, 2026 (in 4 weeks)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.12
Revenue Estimate
$95.2M
Earnings History
Past 12 earnings reports for Ardelyx
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 19, 2026 | Q4 2025 | $0.00Est: $0.01 | -100.0% | $125.2MEst: $117.9M | +6.2% |  10-K |
| Oct 30, 2025 | Q3 2025 | $0.00Est: -$0.06 | +100.0% | $110.3MEst: $100.3M | +10.0% | 10-Q |
| Aug 4, 2025 | Q2 2025 | -$0.08Est: -$0.13 | +38.5% | $97.7MEst: $82.5M | +18.4% | 10-Q |
| May 1, 2025 | Q1 2025 | -$0.17Est: -$0.08 | -112.5% | $74.1MEst: $79.4M | -6.7% | 10-Q |
| Feb 20, 2025 | Q4 2024 | $0.02Est: $0.00 | — | $116.1MEst: $111.2M | +4.5% | 10-K |
| Oct 31, 2024 | Q3 2024 | $0.00Est: -$0.05 | +100.0% | $98.2MEst: $86.6M | +13.4% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$0.07Est: -$0.11 | +36.4% | $73.2MEst: $54.4M | +34.5% | 10-Q |
| May 2, 2024 | Q1 2024 | -$0.11Est: -$0.15 | +26.7% | $46.0MEst: $35.8M | +28.5% | 10-Q |
| Feb 22, 2024 | Q4 2023 | -$0.12Est: -$0.09 | -33.3% | $34.4MEst: $34.2M | +0.4% | 10-K |
| Oct 31, 2023 | Q3 2023 | $0.03Est: -$0.11 | +127.3% | $56.4MEst: $22.8M | +147.7% | 10-Q |
| Aug 2, 2023 | Q2 2023 | -$0.08Est: -$0.12 | +33.3% | $22.3MEst: $15.9M | +40.6% | — |
| May 3, 2023 | Q1 2023 | -$0.13Est: -$0.10 | -30.0% | $11.4MEst: $10.6M | +7.3% | — |